Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Levin, Myron J.
426  Ergebnisse:
Personensuche X
?
1

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevi..:

Levin, Myron J. ; Ustianowski, Andrew ; De Wit, Stephane...
Infectious Diseases and Therapy.  13 (2024)  6 - p. 1253-1268 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Effect of high dose vitamin D supplementation on subsequent..:

Levin, Myron J. ; Ginde, Adit A. ; Schmid, D. Scott...
Vaccine.  42 (2024)  9 - p. 2278-2281 , 2024
Link: https://doi.org/10.1016/..
 
?
3

The economic rationale for cell-based influenza vaccines in..:

Fisman, David ; Giglio, Norberto ; Levin, Myron J....
Human Vaccines & Immunotherapeutics.  20 (2024)  1 - p. , 2024
Link: https://doi.org/10.1080/..
 
?
4

Incidence and clinical outcomes of pneumonia in persons wit..:

Janoff, Edward N. ; Tseng, Hung-Fu ; Nguyen, Jennifer L....
Vaccine.  41 (2023)  31 - p. 4571-4578 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Predictors of 5-Year Persistence of Antibody Responses to Z..:

Weinberg, Adriana ; Scott Schmid, D ; Leung, Jessica...
The Journal of Infectious Diseases.  228 (2023)  10 - p. 1367-1374 , 2023
Link: https://doi.org/10.1093/..
 
?
6

Recruitment of naive CD4+ T cells by the recombinant zoster..:

Laing, Kerry J. ; Ford, Emily S. ; Johnson, Michael J....
Journal of Clinical Investigation.  133 (2023)  23 - p. , 2023
Link: https://doi.org/10.1172/..
 
?
7

A clinical and economic assessment of adjuvanted trivalent ..:

Levin, Myron J. ; Divino, Victoria ; Postma, Maarten J....
Expert Review of Vaccines.  23 (2023)  1 - p. 124-136 , 2023
Link: https://doi.org/10.1080/..
 
?
8

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Preven..:

Levin, Myron J ; Ustianowski, Andrew ; De Wit, Stéphane...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
9

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-e..:

Levin, Myron J ; Ustianowski, Andrew ; Thissen, Jesse...
Open Forum Infectious Diseases.  10 (2023)  Supplement_2 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
10

Innate and Adaptive Cell-Mediated Immune Responses to a COV..:

Weinberg, Adriana ; Johnson, Michael J ; Garth, Krystle...
Open Forum Infectious Diseases.  10 (2023)  12 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
11

Breakthrough SARS-CoV-2 Infections in the PROVENT Preventio..:

Tuffy, Kevin M ; Ahani, Bahar ; Aksyuk, Anastasia A...
The Journal of Infectious Diseases.  228 (2023)  8 - p. 1055-1059 , 2023
Link: https://doi.org/10.1093/..
 
?
12

1097. Risk of Severe COVID-19 Disease in Individuals with D..:

Ku, Jennifer H ; Levin, Myron J ; Luo, Yi...
Open Forum Infectious Diseases.  9 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
13

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophyla..:

Levin, Myron J ; Ustianowski, Andrew ; Thomas, Steven...
Clinical Infectious Diseases.  76 (2022)  7 - p. 1247-1256 , 2022
Link: https://doi.org/10.1093/..
 
?
14

Risk of Severe Coronavirus Disease 2019 Disease in Individu..:

Ku, Jennifer H ; Levin, Myron J ; Luo, Yi...
The Journal of Infectious Diseases.  226 (2022)  5 - p. 757-765 , 2022
Link: https://doi.org/10.1093/..
 
?
15

Development of antibody-dependent cellular cytotoxicity in ..:

Park, Seong Yeon ; Levin, Myron J. ; Canniff, Jennifer...
npj Vaccines.  7 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
1-15